Organization

Department of Biostatistics and Bioinformatics, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC, Duke University, Durham, NC, Duke University Department of Biostatistics and Bioinformatics, Durham, NC, University of Minnesota, Minneapolis, MN, Dana-Farber Cancer Institute, Boston, MA, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, Mount Sinai School of Medicine, New York, NY, Prostate Cancer Foundation, Santa Monica, CA, Department of Medical Oncology and Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, New York, NY, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC

1 abstract

Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,